Cargando…
Teprotumumab: A Review in Thyroid Eye Disease
Teprotumumab (TEPEZZA(®)), a monoclonal antibody that inhibits the insulin-like growth factor 1 receptor (IGF-1R), is the first disease-modifying therapy approved for the treatment of thyroid eye disease (TED) in the USA. In phase II and III clinical trials in adults with active, moderate-to-severe...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718703/ https://www.ncbi.nlm.nih.gov/pubmed/36418673 http://dx.doi.org/10.1007/s40265-022-01804-1 |